ACUMEN PHARMACEUTICALS INC (ABOS)

US00509G2093 - Common Stock

4.21  -0.08 (-1.86%)

After market: 4.21 0 (0%)

ACUMEN PHARMACEUTICALS INC

NASDAQ:ABOS (9/27/2023, 7:09:44 PM)

After market: 4.21 0 (0%)

4.21

-0.08 (-1.86%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)N/A N/A
Ins Owners0.53%
Inst Owners42.61%
Market Cap243.63M
Shares57.87M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts86.15
IPO07-01 2021-07-01
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ABOS Daily chart

Company Profile

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Charlottesville, Virginia and currently employs 39 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The firm's ACU193 is a humanized monoclonal antibody that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The firm's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques. The firm is developing ACU193 for intravenous (IV), administration every four weeks for the treatment of early AD, which is in Phase I clinical trial.

Company Info

ACUMEN PHARMACEUTICALS INC

427 Park St.

Charlottesville VIRGINIA

P: 19253688508.0

CEO: Daniel O'Connell

Employees: 39

Website: https://acumenpharm.com/

ABOS News

News Image8 days ago - Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
News Image8 days ago - Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical...

News Image15 days ago - Market News VideoOversold Conditions For Acumen Pharmaceuticals (ABOS)
News Image21 days ago - Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
News Image21 days ago - Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical...

News Image2 months ago - Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

ABOS Twits

Here you can normally see the latest stock twits on ABOS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example